KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Consolidated Net Income: 2018-2025

Historic Consolidated Net Income for Castle Biosciences (CSTL) over the last 8 years, with Sep 2025 value amounting to -$501,000.

  • Castle Biosciences' Consolidated Net Income fell 122.08% to -$501,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.2 million, marking a year-over-year decrease of 300.86%. This contributed to the annual value of $18.2 million for FY2024, which is 131.75% up from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Consolidated Net Income is -$501,000, which was down 110.99% from $4.6 million recorded in Q2 2025.
  • Castle Biosciences' Consolidated Net Income's 5-year high stood at $9.6 million during Q4 2024, with a 5-year trough of -$29.2 million in Q1 2023.
  • For the 3-year period, Castle Biosciences' Consolidated Net Income averaged around -$5.5 million, with its median value being -$2.5 million (2024).
  • In the last 5 years, Castle Biosciences' Consolidated Net Income tumbled by 1,039.38% in 2023 and then skyrocketed by 471.71% in 2024.
  • Castle Biosciences' Consolidated Net Income (Quarterly) stood at -$6.4 million in 2021, then slumped by 220.65% to -$20.6 million in 2022, then skyrocketed by 87.49% to -$2.6 million in 2023, then surged by 471.71% to $9.6 million in 2024, then plummeted by 122.08% to -$501,000 in 2025.
  • Its Consolidated Net Income was -$501,000 in Q3 2025, compared to $4.6 million in Q2 2025 and -$25.8 million in Q1 2025.